Vertex Branches into Diabetes Field with Semma Therapeutics Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)
Published: 7 Sep-2019
DOI: 10.3833/pdr.v2019.i9.2456 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing to diversify its pipeline away from its flagship cystic fibrosis business, Vertex Pharmaceuticals has agreed to acquire Semma Therapeutics for US$950 M in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS